Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis

Current Pharmaceutical Design

Volumn 12, Issue 35, 2006, Pages 4637-4647

  Schmidt, Lars E ^a   Ring Larsen, H ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Alpha adrenergic agonists; Chronic liver disease; Decompensated liver cirrhosis; Functional renal failure; Hepatorenal syndrome; Vasoconstrictors; Vasopressin analogues

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN II; DOPAMINE; FELYPRESSIN; HYPERTENSIVE AGENT; LYPRESSIN; METARAMINOL; MIDODRINE; MISOPROSTOL; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN A1; PROSTAGLANDIN E1; PROSTAGLANDIN E2; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ABDOMINAL PAIN; BLOOD VOLUME; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG INDICATION; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEPATORENAL SYNDROME; HUMAN; INTESTINE ISCHEMIA; ISCHEMIC COLITIS; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SPLANCHNIC BLOOD FLOW; SURVIVAL; THORAX PAIN; TONGUE DISEASE; UNSPECIFIED SIDE EFFECT; VASODILATATION; VOMITING;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS; SPLANCHNIC CIRCULATION; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 33751510465     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206779010413     Document Type: Review

References (78)

1. Arroyo V, Ginés P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
2. Ginés A, Escorsell A, Ginés P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
3. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49: 729-37.
4. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-5.
5. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34: 1242-51.
6. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.
7. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-95.
8. Gülberg V, Gerbes AL. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1 - effect on survival? Z Gastroenterol 2002; 40: 823-6.
9. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
10. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32: 157-70.
11. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-8.
12. Laffi G, La Villa G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 530-48.
13. Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983; 84: 697-703.
14. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001; 35: 605-12.
15. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Arroyo V, Ginés P, Rodés J, Schrier RW Eds, Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis, and treatment. Malden, Blackwell Science 1999; 307-29.
16. Dagher L, Patch D, Marley R, Moore K, Burroughs A. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients. Aliment Pharmacol Ther 2000; 14: 515-21.
17. Wong PY, Carroll RE, Lipinski TL, Capone RR. Studies on the renin-angiotensin-aldosterone system in patients with cirrhosis and ascites: effect of saline and albumin infusion. Gastroenterology 1979; 77: 1171-6.
18. Wong F, Tobe S, Legault L, Logan AG, Skorecki K, Blendis LM. Refractory ascites in cirrhosis: roles of volume expansion and plasma atrial natriuretic factor level elevation. Hepatology 1993; 18: 519-28.
19. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109: 1917-25.
20. Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002; 16(Suppl 5): 12-23.
21. Guevara M, Ginés P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
22. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
23. Barnardo DE, Baldus WP, Maher FT. Effects of dopamine on renal function in patients with cirrhosis. Gastroenterology 1970; 58: 524-31.
24. Bennett WM, Keeffe E, Melnyk C, Mahler D, Rosch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964-71.
25. Vincenti F, Goldberg LI. Combined use of dopamine and prostaglandin A1 in patients with acute renal failure and hepatorenal syndrome. Prostaglandins 1978; 15: 463-72.
26. Bacq Y, Gaudin C, Hadengue A, Roulot D, Braillon A, Moreau R, et al. Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis. Hepatology 1991; 14: 483-7.
27. Lin SM, Lee CS, Kao PF. Low-dose dopamine infusion in cirrhosis with refractory ascites. Int J Clin Pract 1998; 52: 533-6.
28. Salo J, Gines A, Quer JC, Fernandez-Esparrach G, Guevara M, Gines P, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996; 25: 916-23.
29. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
30. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990; 11: 153-8.
31. Gines A, Salmeron JM, Gines P, Arroyo V, Jimenez W, Rivera F, et al. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993; 17: 220-6.
32. Arroyo V, Bataller R, Guevara M. Treatment of hepatorenal syndrome in cirrhosis. In: Arroyo V, Ginés P, Rods J, Schrier RW Eds, Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis, and treatment. Malden, Blackwell Science 1999; 492-510.
33. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347: 1842-3.
34. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 294-5.
35. Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol 1988; 62: 86E-93E.
36. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002; 36: 374-80.
37. Gornel DL, Lancestremere RG, Papper S, Lowenstein LM. Acute changes in renal excretion of water and solute in patients with Laennec's cirrhosis, induced by the administration of the pressor amine, metaraminol. J Clin Invest 1962; 41: 594-603.
38. Lancestremere RG, Klingler EL Jr, Frisch E, Papper S. Simultaneous determination of cardiac output and renal function in patients with Laennec's cirrhosis during the administration of the pressor amine, metaraminol. J Lab Clin Med 1963; 61: 820-5.
39. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-43.
40. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 2: 1121-5.
41. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin ii and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 1965; 44: 1171-86.
42. Pehl C, Schepp W. Successful therapy of hepatorenal syndrome with norepinephrine. Z Gastroenterol 2000; 38: 945-50.
43. Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P. Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol 1990; 259: R53-R60.
44. Chan WY, Hruby VJ. Natriuretic action of neurohypophysial peptides: effects of agonists and antagonists and implication of natriuretic receptor. J Pharmacol Exp Ther 1988; 246: 597-602.
45. Nonoguchi H, Owada A, Kobayashi N, Takayama M, Terada Y, Koike J, et al. Immunohistochemical localization of V2 vasopressin receptor along the nephron and functional role of luminal V2 receptor in terminal inner medullary collecting ducts. J Clin Invest 1995; 96: 1768-78.
46. Manning PT, Schwartz D, Katsube NC, Holmberg SW, Needleman P. Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985; 229: 395-7.
47. Rector WG Jr. Drug therapy for portal hypertension. Ann Intern Med 1986; 105: 96-107.
48. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994; 203: 72-9.
49. Cohn JN, Tristani FE, Khatri IM. Systemic vasoconstrictor and renal vasodilator effects of PLV-2 (octapressin) in man. Circulation 1968; 38: 151-7.
50. Kew MC, Varma RR, Sampson DJ, Sherlock S. The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 1972; 13: 293-6.
51. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med 1999; 246: 183-90.
52. Lenz K, Druml W, Kleinberger G, Hortnagl H, Laggner A, Schneeweiss B, et al. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut 1985; 26: 1385-6.
53. Lenz K, Hortnagl H, Druml W, Grimm G, Laggner A, Schneeweisz B, et al. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989; 30: 90-6.
54. Lenz K, Hortnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060-7.
55. Evrard P, Ruedin P, Installe E, Suter PM. Low-dose ornipressin improves renal function in the hepatorenal syndrome. Crit Care Med 1994; 22: 363-6.
56. Gülberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
57. Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996; 41: 1054-6.
58. Cervoni JP, Lecomte T, Cellier C, Auroux J, Simon C, Landi B, et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am J Gastroenterol 1997; 92: 2113-4.
59. Le Moine O, el Nawar A, Jagodzinski R, Bourgeois N, Adler M, Gelin M, et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998; 61: 268-70.
60. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.
61. Uriz J, Ginés P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
62. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001; 64: 15-9.
63. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002; 14: 1363-8.
64. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
65. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-8.
66. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002; 14: 153-8.
67. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152-6.
68. Gutman RA, Forrey AW, Fleet WP, Cutler RE. Vasopressor-induced natriuresis and altered intrarenal haemodynamics in cirrhotic man. Clin Sci 1973; 45: 19-34.
69. Kaffy F, Borderie C, Chagneau C, Ripault MP, Larzilliere I, Silvain C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. J Hepatol 1999; 30: 174.
70. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, doubleblind, placebo-controlled, crossover study. Hepatology 2003; 38: 238-43.
71. Rimola A, Gavaler JS, Schade RR, el Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-56.
72. Brown RS Jr, Lombardero M, Lake JR. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996; 62: 1788-93.
73. Lafayette RA, Pare G, Schmid CH, King AJ, Rohrer RJ, Nasraway SA. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. Clin Nephrol 1997; 48: 159-64.
74. Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002; 35: 1179-85.
75. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40: 140-6.
76. Behnia R, Molteni A, Igic R. Angiotensin-converting enzyme inhibitors: mechanisms of action and implications in anesthesia practice. Curr Pharm Design 2003; 9(9): 763-76.
77. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Design 2004; 10(17): 2123-30.
78. Fabris P, Barnes E, Tositti G, Giordani MT, Grasso A, De Lalla F. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Design 2004; 10(17): 2111-22.